Ad www.AngelOne.in
FREE Account Opening + Zero AMC Fees* + MutualFund SIP1
FREE Equity Delivery and MF
Flat ₹20/trade Intra-day/F&O
Ad www.AngelOne.in
IPO Status: Listed [4th Aug 2021 to 6th Aug 2021]
Windlas Biotech, a leading market player in the domestic pharmaceutical formulations contract development and manufacturing company is coming up with an IPO. The IPO opens for subscription on 4 August and closes on 6 August. It is a book building offer that price band is fixed at Rs.448-460 and lot sizes is 30 shares.. Stay updated here to get complete information about the Windlas Biotech including business overview, profitability track record, financial metrics, GMP, live subscription status, allotment, and more.
| IPO Issue Opening Date: | 4th Aug 2021 |
| IPO Issue Closing Date: | 6th Aug 2021 |
| IPO Issue Price: | ₹448-460 Per Share |
| DRHP: | Download DRHP |
| RHP: | Download RHP |
| Anchor List: | Download Anchor List |
| IPO Listing At: | BSE, NSE |
| Retail Quota: | 50.34 |
| IPO Issue Type: | Book Build Issue |
| IPO Issue Size: | ₹401.54 Cr |
| Offer for Sale: | 5,142,067 Eq Shares at ₹448-460 each (Aggregating up to ₹236.54 Cr] |
| Fresh Issue: | ₹165 Cr |
| Face Value: | ₹5 Per Equity Share |
| IPO Discount: | NA |
| Promoter Holding Pre IPO: | 78% |
| Promoter Holding Post IPO: | 65.16% |
| Allotment Status: | Allotment Status |
| BSE Code: | 543329 |
| NSE Code: | WINDLAS |
Get important updates regarding Windlas Biotech IPO tentative timeline covering IPO opening, closing, allotment, and listing dates. Dates are updated as they are announced.
| IPO Activity | Date |
|---|---|
| Basis of Allotment Date* | 11th Aug 2021 |
| Refunds Initiation* | 12th Aug 2021 |
| Credit of Shares to Demat* | 13th Aug 2021 |
| IPO Listing Date* | 16th Aug 2021 |
* - Tentative Dates
| IPO Activity | Date |
|---|---|
| Issue Price | ₹448-460 |
| Market Lot: | 30 Shares |
| 1 Lot Amount: | ₹13800 |
| Min Small HNI Lots(2-10 Lakh): | 450 shares(15 lots) |
| Min Big HNI Lots(10+ Lakh): |
| GMP Date | IPO Price | GMP | Sub2 Sauda Rate | Expected Listing Gain | Last Updated |
|---|---|---|---|---|---|
| 16-08-2021 | 460 | 80 | -- | ₹540 (17.39%) | 16-Aug-2021 8:49 |
Zerodha Trade@20
**The GMP prices shown here are only news related to the grey market. We do not trade/deal in grey market or subject to rates (sub2), nor do we recommend trading in grey market.
Windlas Biotech is a strong market player in the domestic pharmaceutical manufacturing contract development and manufacturing organizations (CDMO) in India. The company provides a complete CDMO solution with a range of offerings from product development to licensing, registration, and commercial manufacturing of generic products comprising complex generics.
It has 3 verticals or SBUs 1. CDMO services and products, 2. Domestic Trade Generics and OTC brands; and 3. Export in high-growth markets. The business generates most of the revenue over 85% from the CDMO segment. The company also offers its own branded trade generic products and looking to the increasing prevalence of chronic diseases (cardiovascular, neuropsychiatry, anti-diabetic, respiratory therapies, etc.), the company aims to launch new complex generic products in the future.
Pfizer Limited, Sanofi India Limited, Cadila Healthcare Limited/ Zydus Healthcare Limited, Emcure Pharmaceuticals Limited, Eris Lifesciences Limited, Intas Pharmaceuticals Limited, and Systopic Laboratories Private Limited are some of the customers of Windlas Biotech. Currently, the firm owns 4 manufacturing plants at Dehradun, Uttarakhand with an aggregated installed capacity of 7,063.83 million tablets/ capsules, 54.46 million pouch/ sachet, and 61.08 million liquid bottles.
| Incorporation | Sector | IPO Issue Size | Website |
| 2001 | Pharmaceutical | ₹401.54 Cr | http://www.windlasbiotech.com/ |
The company intends to utilize the net proceed from the IPO towards the following purposes;
The table below is live update of IPO bidding details from NSE and BSE.
| Day | QIB | NII | RII | Total | |
|---|---|---|---|---|---|
| # of Shares Offered | 1,723,700 (28.09%) | 1,323,766 (21.57%) | 3,088,786 (50.34%) | 6,136,252 | |
| 1 | 4th Aug 2021 17:03 | 0.00x | 0.34x | 6.15x | 3.17x |
| 2 | 5th Aug 2021 17:03 | 0.04x | 1.11x | 13.40x | 7.00x |
| 3 | 6th Aug 2021 18:52 | 24.40x | 15.73x | 24.22x | 22.44x |
| Windlas Biotech Ltd Financials | 31-Mar-2021 | 31-Mar-2020 | 31-Mar-2019 | 31-Mar-2018 |
|---|---|---|---|---|
| Total Assets | ₹296.12 Cr | ₹338.49 Cr | ₹298.18 Cr | ₹289.89 Cr |
| Total Income | ₹430.70 Cr | ₹331.34 Cr | ₹311.52 Cr | ₹356.58 Cr |
| Net Profit/Loss | ₹15.57 Cr | ₹16.21 Cr | ₹63.82 Cr | ₹11.20 Cr |
Last Updated on 27-Sep-2021 10:39:43
